- Home
- ACP vs IRWD Comparison
ACP vs IRWD Comparison
Compare ACP & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACP | IRWD |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.4M | 687.4M |
| IPO Year | 2010 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ACP | IRWD |
|---|---|---|
| Price | $4.35 | $3.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.10 |
| AVG Volume (30 Days) | 966.9K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 17.79% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $59.19 |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | ★ N/A | $6.55 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $4.26 | $1.43 |
| 52 Week High | $5.76 | $5.78 |
Technical Indicators
Market Signals| Indicator | ACP | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 33.68 | 43.50 |
| Support Level | N/A | $3.04 |
| Resistance Level | $5.32 | $3.96 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 27.00 | 37.12 |
Price Performance
Historical ComparisonAbout ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.